TORONTO, June 24 /CNW/ - Amorfix Life Sciences, a company focused on
treatments and diagnostics for brain wasting diseases, today announced that
its diagnostic test for the presence of aggregated Abeta in Alzheimer's
disease is ready to be applied to patient samples. The company has adapted its
test to specifically detect aggregated Abeta protein (amyloid) in femtogram
quantities (ten parts per trillion) from an Alzheimer's brain when it is
spiked into plasma or cerebral spinal fluid (CSF).
"Our AD diagnostic assay is now the most sensitive test available for
Abeta protein based on our survey of existing tests. We have achieved the
sensitivity required to test human Alzheimer's blood and CSF for aggregated
Abeta, a hallmark of Alzheimer's disease," said Dr. Neil Cashman, Chief
Scientific Officer of Amorfix. "In addition, we believe we can further improve
the assay sensitivity by incorporating technology similar to that developed
for our EP-vCJD(TM) Blood Screening Assay."
The company obtained ethical approval to collect and use blood from
Alzheimer's patients for assay validation, and has already obtained the
necessary blood and CSF samples from Alzheimer's patients and normal controls
to begin testing.
Alzheimer's disease is associated with an accumulation of protein
aggregates, called amyloid, in the brain. Research has shown that amyloid
results from aggregation of misfolded Abeta protein. The Amorfix AD diagnostic
test has been developed to detect aggregated Abeta, the characteristic feature
of Alzheimer's disease, in a blood sample or CSF whereas existing assays only
detect Abeta. The company believes that detection of aggregated Abeta in blood
or CSF would represent a significant advancement in the search for a reliable
indicator to show evidence of Alzheimer's disease. The company believes that
CSF will have a higher concentration of Abeta aggregates because they
originate from the brain and are not diluted in the plasma. There are
currently no reliable methods for diagnosing this disease prior to death.
Amorfix hypothesizes that aggregated Abeta passes from the brain to the CSF
and makes its way into the blood system through a known physiological pathway.
As there is no test for aggregated Abeta, the presence of or amount of
aggregated Abeta in blood or CSF of Alzheimer's patients is not known.
"The Amorfix team has made significant progress in the development of a
test to diagnose Alzheimer's disease since our original investment. We
continue to be supportive of their efforts to find a diagnostic solution to
such a devastating disease," commented Dr. Christian Burks, President & CEO of
Ontario Genomics Institute.
Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing
therapeutic products and diagnostic devices targeting brain-wasting diseases
including ALS, Alzheimer's Disease, Parkinson's Disease and variant
Creutzfeldt-Jakob Disease (vCJD). Amorfix's proprietary Epitope Protection(TM)
(EP) technology enables it to specifically identify very low levels of
aggregated misfolded proteins (AMP) in a sample of normal protein. Aggregated
misfolded proteins are a common element of many brain wasting diseases and the
ability to identify AMPs and understand their structure and mechanism of
folding are the first steps to developing new treatments for these devastating
diseases. Amorfix's lead programs are a diagnostic blood screening test for
vCJD and a therapy for ALS.
This information release may contain certain forward-looking information.
Such information involves known and unknown risks, uncertainties and other
factors that may cause actual results, performance or achievements to be
materially different from those implied by statements herein, and therefore
these statements should not be read as guarantees of future performance or
results. All forward-looking statements are based on the Company's current
beliefs as well as assumptions made by and information currently available to
it as well as other factors. Readers are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the date of this
press release. Due to risks and uncertainties, including the risks and
uncertainties identified by the Company in its public securities filings,
actual events may differ materially from current expectations. The Company
disclaims any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or
For further information:
For further information: Dr. George Adams, President & Chief Executive
Officer, Amorfix Life Sciences Ltd., Tel: (416) 847-6959, Fax: (416) 847-6899,
email@example.com; James Parsons, Chief Financial Officer, Amorfix Life
Sciences Ltd., Tel: (416) 847-6929, Fax: (416) 847-6899,